Quick Order Cart

Cat. No. ARG1460

FNBP1L Knockout Raji Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Bone

  • Disease:

    Burkitt lymphoma

The FNBP1L Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population offering a loss-of-function model of the actin-regulatory scaffold protein FNBP1L in a B lymphocyte background. Derived from the Raji Burkitt lymphoma line, these cells enable investigation of how FNBP1L-mediated CDC42??N-WASP??Arp2/3 signaling influences cell migration, endocytosis, and filopodia formation. This knockout model is ideal for functional studies in cancer and immune cell biology, supporting assays such as Western blotting, immunofluorescence, and migration/invasion tests. By disrupting FNBP1L interactions with formins and N-WASP, researchers can probe pathways relevant to B-cell malignancies and actin dynamics.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Raji

    Cell Type

    B cell line

    Sex of Donor

    Male

    Age

    11 years

    Derived From Site

    In situ; Maxilla

    Gene Name

    FNBP1L

    Gene Identifier

    NCBI Gene ID 54874

    Morphology

    Lymphoblast-like

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    RPMI 1640

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% COâ‚‚

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The FNBP1L Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line. This product provides a loss-of-function model for studying FNBP1L by disrupting the gene across the population, enabling assessment of its collective impact on cell behavior without clonal artifacts. The polyclonal format is well-suited for bulk functional assays where heterogeneity reflects the edited pool, and it avoids biases associated with monoclonal selection.

Raji is an EBV-transformed B lymphoblastoid cell line from a Burkitt lymphoma patient, serving as a model for B-cell malignancies and immune function. These suspension cells express surface IgM and MHC molecules, allowing studies of antigen presentation and B-cell receptor signaling. Their rapid growth and genetic tractability make Raji a standard platform for investigating lymphoma biology and testing therapeutics.

FNBP1L is a scaffold protein that links CDC42 and Rho GTPase signaling to actin polymerization. Activated downstream of receptors such as EGFR, FNBP1L recruits N-WASP and formins (FMNL2, FMNL3) to the Arp2/3 complex, driving filopodia formation and membrane protrusion. This pathway??CDC42 ?? FNBP1L ?? N-WASP ?? Arp2/3??controls cell migration, endocytosis, and synaptic plasticity. FNBP1L also interacts with SH3 domain-containing proteins, integrating multiple inputs to regulate actin dynamics.

In Raji B cells, actin remodeling is critical for immune synapse assembly, antigen internalization, and migration. Knockout of FNBP1L in this context allows researchers to dissect how loss of this scaffold affects B-lymphocyte functions and lymphoma cell invasiveness. Because Raji cells are widely used in cancer and immunology, this model provides a direct system to study the role of FNBP1L in B-cell malignancies and to evaluate its contribution to processes such as tumor cell dissemination and immune evasion.

The polyclonal knockout population supports diverse applications: Western blotting to confirm FNBP1L depletion, immunofluorescence for actin and filopodia analysis, transwell migration and invasion assays, and endocytosis assays using fluorescent ligands. Co-immunoprecipitation can probe altered protein interactions with N-WASP or formins. These cells are also useful as a negative control in CDC42 signaling studies or for compound screening. For further information, contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)